# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# **FORM 8-K**

# CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 10, 2017

# **REACTIVE MEDICAL INC.**

(Exact name of registrant as specified in its charter)

333-199213

33-1220924

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

29 Fitzwiliam Street Upper, Dublin 2 Ireland

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code +353 (1) 443 3527

# KNIGHT KNOX DEVELOPMENT CORP.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 5.03 Amendments to Articles of Incorporation or Bylaws

#### Item 8.01 Other Items

As previously announced, on January 19, 2017, a majority of stockholders of our company and our board of directors approved a change of name of our company from Knight Knox Development Corp. to Reactive Medical Inc. and an increase to our authorized capital from 75,000,000 shares of common stock, par value \$0.001 to 150,000,000 shares of common stock, par value \$0.001 and 50,000,000 shares of preferred stock, par value \$0.001.

The change of name has been reviewed by the Financial Industry Regulatory Authority ("FINRA") and has been approved for filing with an effective date of February 10, 2017. Our company also requested a change of ticker symbol to reflect the change of name.

The change of name will become effective with the Over-the-Counter Bulletin Board at the opening of trading on February 10, 2017 under the symbol "RMED". Our new CUSIP number is 75524H101.

### Item 9.01 Financial Statements and Exhibits

3.1 Certificate of Amendment filed with the Nevada Secretary of State on February 2, 2017 with an effective date of February 10, 2017.

#### 2

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REACTIVE MEDICAL INC.** 

/s/ Peter O'Brien Peter O'Brien President

Date February 10, 2017

3



BARBARA K. CEGAVSKE Secretary of State 202 North Canson Street Carson City, Nevada 89701-4201 (775) 684-6708 Website: www.nvsos.gov

Filed in the office of تعنید الرومید Barbara K, Cegavske Secretary of State State of Nevada	Document Number 20170051976-38
	Filing Date and Time 02/02/2017 3:40 PM
	Entity Number E0258042011-1

# (PURSUANT TO NRS 78.385 AND 78.390)

USE BLACK INK OHLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1. Name of corporation:

KNIGHT KNOX DEVELOPMENT CORP.

2. The articles have been amended as follows: (provide article numbers, if available)

Article 1.

Name of Corporation: Reactive Medical Inc.

Article 3.

Authorized Stock: 150,000,000 shares of common stock, with a par value of \$0.001 per share and 50,000,000 shares of preferred stock, with a par value of \$0.001 per share.

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation\* have voted in favor of the amendment is: 78.5%

4. Effective date and time of filing: (optional) Date: February 10, 2017 Time:

(must not be later than 90 days after the certificate is filed)

5. Signature: (required)

Signature of Officer

"If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
This form must be accompanied by appropriate fees.
Nevade Secretary of Stele Arrend Parti-Ater
Reviews: 15-15